CAncer multidrug resistance: progress in understanding the molecular basis drug resistance in cancer promises more effective treatments

Article Abstract:

The failure of many forms of chemotherapy is caused by the development of resistant cancers.

Brief Article

---

Phage-inspired antibiotics?

Article Abstract:

Bacteriophages an important genetic and a potential antibacterial therapeutics evolved multiple strategies to interfere with bacterial growth and the phage products could be used to validate targets, develop screen and even form basis of novel small molecule therapeutics. Bacteriophages are highly specific and often target not just a single species but also a small sub group within that species.

Bacteriostats, Therapeutic Procedures, Methods, Usage, Therapeutics, Antibacterial agents, Bacteriophages

---

HSP-90 inhibitors promise to complement cancer therapies

Article Abstract:

Pivotal clinical trials will be well underway by the end of 2006 in a new class of drugs that inhibit heat shock protein 90 (HSP-90), a stress-induced molecule abundant in tumors and fungal infections, with two companies Kosan Biosciences and NeuTec Pharma vying for first-in-field status with drugs that take different approaches to squelching HSP-90. Drugs addressing this class of drug target could prove to be a significant complement to existing cancer therapies, with the first to market reaping the most benefits.

Product development, Drugs, Anticancer Drugs, United Kingdom, Biological products industry, Cancer, Antimitotic agents, NeuTec Pharma, Kosan Biosciences Inc.

Similar abstracts:

• Abstracts: Tumor angiogenesis-new drugs on the block: angeogenisis inhibitors could represent adjunct to traditional cancer treatments, but the most effective routes for therapeutic intervention remain unclear
• Abstracts: Kodak revamps Medalist program for added assistance and incentives. Booming PC sales highlight need for sound recycling solutions
• Abstracts: The use of cysteine proteinase inhibitors to engineer resistance against potyviruses in transgenic tobacco plants
• Abstracts: Investors' hopes dashed as trusts go south: for investment trust buyers and management groups, the past year has been little short of a nightmare with performances tumbling and discounts widening
• Abstracts: Integrating cell-level kinetic modeling into the design of engineered protein therapeutics. The single cell as a microplate well

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.